Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
9.86
+0.08 (0.82%)
Nov 13, 2026, 4:00 PM EST - Market closed
Contineum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
387.16M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 412.49M |
| Alector | 173.47M |
| ARS Pharmaceuticals | 122.14M |
| Fennec Pharmaceuticals | 66.37M |
| C4 Therapeutics | 32.28M |
| Opus Genetics | 7.91M |
| YD Bio | 1.24M |
| Lyell Immunopharma | 15.00K |
CTNM News
- 3 days ago - Contineum Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 6 days ago - Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial - Business Wire
- 11 days ago - Contineum reports Q3 EPS (49c), consensus (45c) - TheFly
- 11 days ago - Contineum Therapeutics Reports Third-Quarter 2026 Financial Results - Business Wire
- 11 days ago - Contineum Therapeutics Earnings release: Q3 2026 - Filings
- 11 days ago - Contineum Therapeutics Quarterly report: Q3 2026 - Filings
- 12 days ago - Contineum Therapeutics Slides: Corporate presentation - Filings
- 16 days ago - Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference - Business Wire